Skip to main content

Toronto, Ontario–(Newsfile Corp. – March 21, 2022) – Lophos Pharmaceuticals Inc., a Canadian psychedelic research company focused on drug cultivation and development, engages KGK Science Inc. to assess a pathway to the peyote market sustainably grown natural health products (NHPs) derived. Peyote has legal status in Canada, but mescaline – the drug derived from the plant – remains a Schedule 3 controlled substance.

“Lophos is currently exploring the potential benefits of a peyote-derived natural health product with support from KGK Science. Peyote cultivation presents challenges, and the thirteen-year natural regrowth cycle is a major threat to the endangered plant. AT Lophos, we are looking for accelerated and responsible cultivation techniques to reduce the long growth cycle. “The goal is to provide our partners with therapeutic derivatives of sustainably grown peyote.” – Claire Stawnyczy, Founder and CEO of Lophos

With a focus on natural health products (NHPs), potential pathways to market will be evaluated based on safety and health requirements, quality specifications for peyote-derived inputs, and permitted claims on the product. label for packaging and sale.

“We are very pleased to engage with Lophos Inc. Peyote and mescaline in general are currently underrepresented in the psychedelic medicine industry, given their traditional medicinal uses. Lophos provides a sustainable supply of cacti from a critical importance in the marketplace. We plan to use our expertise in natural health products to help Lophos bring innovative and safe products to market for the Canadian consumer.” – Najla Guthrie, President and CEO of KGK Science

For more information please contact:
Alex Krause – Cushion Communications Inc.
[email protected]

ABOUT LOPHOS
Lophos is a bioscience company specializing in peyote research, cultivation, conservation and drug development. We develop new therapies and natural health treatments that aim to restore and improve the quality of life of patients. Using advanced cultivation and harvesting techniques, Lophos Pharmaceuticals will provide our partners with medical-grade inputs and our patients with access to safe and effective mescaline treatments.

ABOUT KGK SCIENCE
Founded in 1997, KGK is a leading North American contract research organization based in London, Ontario, primarily providing high quality clinical research trials with a focus on the nutraceutical, cannabis and psychedelic industries. emerging. The company has successfully assisted hundreds of companies with custom clinical trials and claim substantiation strategies to move products into global markets. KGK’s other existing service lines include expert regulatory support and compliance solution, participant recruitment, research support services and advisory services. On a rough basis, the company has produced 150 publications to date, executed over 400 clinical trials in over 40 indications, amassed 25,000 participants in its database and collected 10 million data points.

ABOUT DIGITAL WELLNESS SCIENCES
Wellbeing Digital Sciences Inc. (formerly KetamineOne Capital Limited) is an evidence-based healthcare company focused on innovative clinical solutions, artificial intelligence-based digital therapies and contract research. Its mission is supported by a network of North American clinics that provide ketamine-assisted therapies and other types of treatment to patients, as well as a contract research organization that offers clinical trial services to clients pursuing drug development. Essentially, the company exists to make breakthrough treatments more accessible and to provide patients with transformational experiences.

Forward-looking statements
This press release contains “forward-looking information” within the meaning of applicable Canadian securities laws. These statements relate to future events or future performance. Use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “plan”, “estimate” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company’s current beliefs or assumptions as to the outcome and timing of such future events. The forward-looking information contained in this press release includes information regarding the Company’s psychedelic program. Forward-looking information is based on reasonable assumptions that have been made by the Company as of the date of the information and is subject to known and unknown risks, uncertainties and other factors that may cause results or events actuals differ materially from those anticipated in the forward-looking information. Given these risks, uncertainties and assumptions, you should not place undue reliance on these forward-looking statements. The forward-looking information contained in this press release is made as of the date hereof, and the Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as necessary. by applicable securities laws. The foregoing statements expressly qualify any forward-looking information contained herein.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/117448